| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| Other Sizes |
| Targets |
There is no specific pharmacological receptor target; DOSPA is a cationic lipid whose spermine head group binds and condenses negatively charged nucleic acids, and the hydrophobic chains anchor it into lipid bilayers; formulated with DOPE, it forms liposomes that deliver DNA or mRNA into cells.
|
|---|---|
| ln Vitro |
In vitro, DOSPA formulated with DOPE efficiently transfects plasmid DNA and mRNA into cells, including NIH3T3 fibroblasts, increasing reporter gene (β-galactosidase or luciferase) expression; transfection efficiency depends on the DOSPA-to-DOPE ratio and nucleic acid-to-lipid ratio, and cytotoxicity is dose-dependent.
|
| ln Vivo |
In vivo, DOSPA-containing liposomes and lipid nanoparticles deliver nucleic acids to tissues after systemic or local administration, with expression of encoded proteins in target organs; biodistribution and tolerability depend on particle size, surface charge, and dose, and DOSPA-based formulations are investigated for gene therapy and mRNA vaccine applications.
|
| Enzyme Assay |
DOSPA is characterized physicochemically rather than by enzyme or receptor binding; methods include dynamic light scattering for particle size and zeta potential, gel electrophoresis for nucleic acid condensation, and fluorescence or reporter assays for transfection efficiency; lipid purity is assessed by HPLC or thin-layer chromatography.
|
| Cell Assay |
Cells (e.g., NIH3T3, HEK293) are seeded and transfected with DOSPA/DOPE liposomes containing plasmid DNA or mRNA; reporter gene expression is measured by luciferase or β-galactosidase assays, transfection efficiency by flow cytometry or fluorescence microscopy, and cytotoxicity by metabolic activity assays.
|
| Animal Protocol |
Mice or rats receive DOSPA-containing liposomes or lipid nanoparticles by intravenous, intramuscular, or local administration; reporter protein expression in tissues is measured by ELISA or imaging, biodistribution of nucleic acids is assessed by RT-qPCR or fluorescence, and toxicity is monitored by body weight, serum biochemistry, and histopathology.
|
| References |
| Molecular Formula |
C54H115CL5N6O3
|
|---|---|
| Molecular Weight |
1073.79431176186
|
| Exact Mass |
1072.744
|
| CAS # |
282533-23-7
|
| Related CAS # |
682737-28-6 (cation);913238-93-4 (S-isomer cation);913238-93-4 (Chloride HCl);282533-23-7 (chlroide 4HCl); 156180-29-9 (bromide); 156180-29-9 (chloride); 913194-16-8 (S-isomer Chloride 4HCl);
|
| PubChem CID |
155906221
|
| Appearance |
Typically exists as solid at room temperature
|
| tPSA |
124
|
| Hydrogen Bond Donor Count |
9
|
| Hydrogen Bond Acceptor Count |
8
|
| Rotatable Bond Count |
52
|
| Heavy Atom Count |
68
|
| Complexity |
979
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
CCCCCCCC/C=C\CCCCCCCCOCC(C[N+](C)(C)CCNC(=O)C(CCCNCCCN)NCCCN)OCCCCCCCC/C=C\CCCCCCCC.Cl.Cl.Cl.Cl.[Cl-]
|
| InChi Key |
RYQDMINLUXGGGS-AYXXFMLISA-N
|
| InChi Code |
InChI=1S/C54H110N6O3.5ClH/c1-5-7-9-11-13-15-17-19-21-23-25-27-29-31-33-35-48-62-51-52(63-49-36-34-32-30-28-26-24-22-20-18-16-14-12-10-8-6-2)50-60(3,4)47-46-59-54(61)53(58-45-39-42-56)40-37-43-57-44-38-41-55;;;;;/h19-22,52-53,57-58H,5-18,23-51,55-56H2,1-4H3;5*1H/b21-19-,22-20-;;;;;
|
| Chemical Name |
2-[2,5-bis(3-aminopropylamino)pentanoylamino]ethyl-[2,3-bis[(Z)-octadec-9-enoxy]propyl]-dimethylazanium;chloride;tetrahydrochloride
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80: Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 :Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400  (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 0.9313 mL | 4.6564 mL | 9.3128 mL | |
| 5 mM | 0.1863 mL | 0.9313 mL | 1.8626 mL | |
| 10 mM | 0.0931 mL | 0.4656 mL | 0.9313 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.